Business · 26/01/1995Updated: 10/18/2026 · 1 min read
FDA Sets Regulatory Review Period for NetrexinSUPTM Patent Extension
Summary
The US Food and Drug Administration has determined the regulatory review period for the patent extension of NetrexinSUPTM, a medication developed by a pharmaceutical company.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →